Renvela 800 mg Norge - norsk - Statens legemiddelverk

renvela 800 mg

orifarm as - sevelamerkarbonat - tablett, filmdrasjert - 800 mg

Simulect Den europeiske union - norsk - EMA (European Medicines Agency)

simulect

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunsuppressive - simulect er indisert for profylakse av akutt organavstødning i de-novo allogen nyretransplantasjon hos voksne og pediatriske pasienter (1-17 år). det er til å bli brukt samtidig med ciclosporin for microemulsion - og kortikosteroid-basert immunsuppresjon hos pasienter med panel reaktiv antistoffer mindre enn 80%, eller i en trippel vedlikehold immunsuppressiv diett som inneholder ciclosporin for microemulsion, kortikosteroider og enten azatioprin eller mycophenolate mofetil.

Nulojix Den europeiske union - norsk - EMA (European Medicines Agency)

nulojix

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunsuppressive - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Valtrex 250 mg Norge - norsk - Statens legemiddelverk

valtrex 250 mg

glaxosmithkline as - valaciklovirhydroklorid - tablett, filmdrasjert - 250 mg

Valtrex 500 mg Norge - norsk - Statens legemiddelverk

valtrex 500 mg

glaxosmithkline as - valaciklovirhydroklorid - tablett, filmdrasjert - 500 mg

Idefirix Den europeiske union - norsk - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressive - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Enspryng Den europeiske union - norsk - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressive - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Augmentin 400 mg/5 ml / 57 mg/5 ml Norge - norsk - Statens legemiddelverk

augmentin 400 mg/5 ml / 57 mg/5 ml

orifarm as - amoksicillintrihydrat / kaliumklavulanat - pulver til mikstur, suspensjon - 400 mg/5 ml / 57 mg/5 ml

Augmentin 500 mg / 125 mg Norge - norsk - Statens legemiddelverk

augmentin 500 mg / 125 mg

orifarm as - amoksicillintrihydrat / kaliumklavulanat - tablett, filmdrasjert - 500 mg / 125 mg

Cancidas (previously Caspofungin MSD) Den europeiske union - norsk - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika for systemisk bruk - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.